VIRTUAL SYMPOSIUMCustomizing first-line BTK inhibitors for CLL
Wednesday, October 23, 2024
18:30–19:30 BST
Agenda
Welcome and introductions
- Introduction to the Lymphoma Hub
- Educational objectives and pre-symposium test
- Introduction to the speakers
Unmet needs with BTKis in CLL
- Overview of the current treatment guidelines for BTKis
- Real-world experience with BTKis
- Impact of mutation pattern with BTKis and clinical implications
- Live Q&A with the audience
BTKis: Current and future perspectives
- Overview of emerging BTKis for CLL
- Key efficacy and safety data from clinical trials
- Live Q&A with the audience
BTKis in clinical practice for CLL: Case study clinic
- Interactive case studies and panel discussion to review optimal treatment selection for CLL in patient subgroups, including high- versus low-risk patients, sequencing strategies, dosing flexibility, and the role of minimal residual disease
- Live Q&A with the audience
Learning objectives
Upon completion of this activity, participants should be able to:
- Describe novel therapeutic targets in CLL and explain the mechanisms of action for new agents.
- Recall the latest data for new agents, including their regulatory status in CLL, and describe the rationale for selecting such treatments based on previous treatments and patient-related factors.
- Describe the adverse event profiles of novel agents, and state how adverse events could be managed in clinical practice.
Our speakers
Meet our panel of experts
Gilles Salles
Memorial Sloan Kettering Cancer Center
New York, US
Paolo Ghia
Università Vita-Salute San Raffaele
Milan, IT
Francesc Bosch
Vall d'Hebron Barcelona Hospital Campus
Barcelona, ES
About SES
Delivering streamlined independent medical education to enhance clinical practice. SES hubs allow time-stretched healthcare professionals to easily access curated scientific, medical, and clinical information that expedites their learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, our hubs support healthcare professionals worldwide with up-to-date, accessible, and impactful educational content.
About the Lymphoma Hub
The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
The Lymphoma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.